{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:23:24Z","timestamp":1787664204186,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda (China) Holdings Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of vedolizumab (VDZ) in Asian patients with IBD, including Crohn\u2019s disease (CD) and Ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, EMBASE, the Cochrane Library, Web of Science, CBM, CNKI, Wanfang, and VIP for real-world studies assessing intravenous VDZ in Asian IBD patients. Primary outcomes were clinical remission, response and endoscopic remission. Secondary outcomes encompassed corticosteroid-free clinical remission, endoscopic response, complete endoscopic remission, C-reactive protein remission, faecal calprotectin normalization, treatment persistence rate and safety variables. Meta-analysis was performed for CD and UC across induction (6\u201314 weeks), medium term (22\u201330 weeks), and long term (over 48 weeks) using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine studies with 2395 patients were included. Induction clinical remission and response was 61.15% and 57.48% for CD, and 40.07% and 64.72% for UC. Medium-term clinical remission and response was 60.72% and 64.32% for CD, and 43.51% and 64.87% for UC. Long-term clinical remission and response for CD was 45.83% and 44.55%, for UC was 56.14% and 61.35%. Endoscopic remission improved across induction, medium term, and long-term for CD (11.11%, 18.41% and 36.42%) and UC (43.19%, 54.27% and 66.72%). Within the longest follow up of 52 weeks, adverse event rate ranged widely from 6.67% to 61.54% for CD and 29.69% to 75.38% for UC. Chinese patients and both biologic-na\u00efve and biologic-experienced patients showed similar favorable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>VDZ demonstrated overall favourable effectiveness in Asian IBD patients, with a safety profile aligned with global data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The protocol was registered on National Institution for Health and Care Research (registration number CRD420251000408).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04975-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:55:45Z","timestamp":1781225745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4940-5303","authenticated-orcid":false,"given":"Yubei","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8199-6427","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1879-2708","authenticated-orcid":false,"given":"Lifei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-5304","authenticated-orcid":false,"given":"Duowu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"9853","key":"4975_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605. https:\/\/doi.org\/10.1016\/s0140-6736(12)60026-9.","journal-title":"Lancet"},{"issue":"10080","key":"4975_CR2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/s0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(16)32126-2.","journal-title":"Lancet"},{"issue":"4","key":"4975_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","volume":"14","author":"EJ Irvine","year":"2008","unstructured":"Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14(4):554\u201365. https:\/\/doi.org\/10.1002\/ibd.20301.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4975_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global,regional, and national burden of inflammatory bowel disease in 195 countries and territories,1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4975_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5217\/ir.2021.00104","volume":"20","author":"EM Song","year":"2022","unstructured":"Song EM, Yang SK. Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res. 2022;20(4):418\u201330. https:\/\/doi.org\/10.5217\/ir.2021.00104.","journal-title":"Intest Res"},{"issue":"5","key":"4975_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","volume":"148","author":"B Bressler","year":"2015","unstructured":"Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035\u2013e583. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.001.","journal-title":"Gastroenterology"},{"issue":"9","key":"4975_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(9):1324\u201338. https:\/\/doi.org\/10.1038\/ajg.2015.233.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"4975_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"SC Shah","year":"2016","unstructured":"Shah SC, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice. J Am Gastroenterological Association. 2016;14(9):1245\u2013e558. https:\/\/doi.org\/10.1016\/j.cgh.2016.01.015.","journal-title":"J Am Gastroenterological Association"},{"issue":"12","key":"4975_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/life11121375","volume":"11","author":"K Wagatsuma","year":"2021","unstructured":"Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life. 2021;11(12):1375.","journal-title":"Life"},{"issue":"3","key":"4975_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","volume":"50","author":"LP Bruner","year":"2023","unstructured":"Bruner LP, White AM, Proksell S. Inflammatory Bowel Disease. Prim Care. 2023;50(3):411\u201327. https:\/\/doi.org\/10.1016\/j.pop.2023.03.009.","journal-title":"Prim Care"},{"issue":"1","key":"4975_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000512805","volume":"6","author":"P Debnath","year":"2021","unstructured":"Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis. 2021;6(1):1\u201317. https:\/\/doi.org\/10.1159\/000512805.","journal-title":"Inflamm Intest Dis"},{"issue":"8","key":"4975_CR12","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ibd.21896","volume":"18","author":"A Parikh","year":"2012","unstructured":"Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470\u20139. https:\/\/doi.org\/10.1002\/ibd.21896.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"4975_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","volume":"161","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Loftus EV Jr., Colombel JF, Danese S, Rogers R, Bornstein JD, et al. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 2021;161(4):1156\u2013e673. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.015.","journal-title":"Gastroenterology"},{"issue":"8","key":"4975_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739.","journal-title":"N Engl J Med"},{"issue":"8","key":"4975_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2013;369(8):699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","journal-title":"N Engl J Med"},{"issue":"11","key":"4975_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s40265-014-0253-1","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Vedolizumab. First Global Approval. Drugs. 2014;74(11):1293\u2013303. https:\/\/doi.org\/10.1007\/s40265-014-0253-1.","journal-title":"Drugs"},{"issue":"1","key":"4975_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5217\/ir.2019.09159","volume":"19","author":"CJ Ooi","year":"2021","unstructured":"Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, et al. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res. 2021;19(1):71\u201382. https:\/\/doi.org\/10.5217\/ir.2019.09159.","journal-title":"Intest Res"},{"issue":"1","key":"4975_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40273-019-00841-1","volume":"38","author":"L Hernandez","year":"2020","unstructured":"Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, et al. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Na\u00efve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. PharmacoEconomics. 2020;38(1):69\u201384. https:\/\/doi.org\/10.1007\/s40273-019-00841-1.","journal-title":"PharmacoEconomics"},{"issue":"11","key":"4975_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/ibd\/izac269","volume":"29","author":"WC Lin","year":"2023","unstructured":"Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, et al. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflamm Bowel Dis. 2023;29(11):1730\u201340. https:\/\/doi.org\/10.1093\/ibd\/izac269.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"4975_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","volume":"113","author":"N Narula","year":"2018","unstructured":"Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113(9):1345. https:\/\/doi.org\/10.1038\/s41395-018-0162-0.","journal-title":"Am J Gastroenterol"},{"key":"4975_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4975_CR22","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JP, Altman DG, Group obotCSM. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. 2019:241\u201384.","DOI":"10.1002\/9781119536604.ch10"},{"key":"4975_CR23","unstructured":"Wells GA, Shea B, O\u2019Connell Da, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"4975_CR24","volume-title":"Systematic Evidence Reviews and Clinical Practice Guidelines","author":"L National Heart","year":"2014","unstructured":"National Heart L, Institute B. Quality assessment tool for before-after (pre-post) studies with no control group. Systematic Evidence Reviews and Clinical Practice Guidelines. Washington DC: National Institutes of Health; 2014."},{"issue":"1","key":"4975_CR25","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41598-023-28566-4","volume":"13","author":"D Anbarserry","year":"2023","unstructured":"Anbarserry D, Mosli M, Qari Y, Saadah O, Bokhary R, Esmat A, et al. The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. Sci Rep. 2023;13(1):1771. https:\/\/doi.org\/10.1038\/s41598-023-28566-4.","journal-title":"Sci Rep"},{"issue":"10","key":"4975_CR26","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.14309\/01.ajg.0000950788.56141.31","volume":"118","author":"BL Chen","year":"2023","unstructured":"Chen BL, Xie L, Liu YM, Chen MH. Clinical Effectiveness of Vedolizumab in Chinese Crohn\u2019s Disease Patients: Results From the VALUE Study. Am J Gastroenterol. 2023;118(10):S211\u20133.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4975_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3760\/cma.j.cn311367-20221202-00598","volume":"43","author":"LJ Jiang","year":"2023","unstructured":"Jiang LJ, Chen L, Chen YF, Chen YR, Chen H. Observation on the efficacy of vedolizumab in the treatment of patients with active Crohn\u2032s disease. Chin J Digestion. 2023;43(6):395\u2013400. https:\/\/doi.org\/10.3760\/cma.j.cn311367-20221202-00598.","journal-title":"Chin J Digestion"},{"issue":"12","key":"4975_CR28","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ibd\/izaa361","volume":"27","author":"J Kim","year":"2021","unstructured":"Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, et al. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis. 2021;27(12):1931\u201341. https:\/\/doi.org\/10.1093\/ibd\/izaa361.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4975_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.dld.2018.07.040","volume":"51","author":"U Kopylov","year":"2019","unstructured":"Kopylov U, Avni-Biron I, Ron Y, Koslowsky B, Waterman M, Daher S, et al. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. Dig Liver Dis. 2019;51(1):68\u201374. https:\/\/doi.org\/10.1016\/j.dld.2018.07.040.","journal-title":"Dig Liver Dis"},{"issue":"10","key":"4975_CR30","first-page":"767","volume":"53","author":"SX Liu","year":"2022","unstructured":"Liu SX, Zhong W, Xia ZS, Zhong YQ. Clinical efficacy of vedolizumab for inflammatory bowel disease. New Med. 2022;53(10):767\u201373.","journal-title":"New Med"},{"issue":"42","key":"4975_CR31","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.3760\/cma.j.cn112137-20220409-00760","volume":"102","author":"B Lu","year":"2022","unstructured":"Lu B, Liu ZS, Zheng WY, Bai XY, Yang H, Qian JM. Short-term efficacy and safety of vedolizumab in patients with inflammatory bowel disease. Natl Med J China. 2022;102(42):3388\u201394. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20220409-00760.","journal-title":"Natl Med J China"},{"issue":"3","key":"4975_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3760\/cma.j.cn101480-20220110-00009","volume":"06","author":"J Tang","year":"2022","unstructured":"Tang J, Deng J, Huang ZC, Huang ZP, Guo HL, Diao N, et al. The real-world efficacy and safety of vedolizumab in the treatment of active Crohn\u2032s disease: a single center retrospective study. Chin J Inflamm Bowel Dis. 2022;06(3):217\u201322. https:\/\/doi.org\/10.3760\/cma.j.cn101480-20220110-00009.","journal-title":"Chin J Inflamm Bowel Dis"},{"issue":"12","key":"4975_CR33","first-page":"1591","volume":"34","author":"QH Tao","year":"2022","unstructured":"Tao QH, Lv H. The predictive value of fecal calprotectin level for the efficacy of vidalizumab in the treatment of patients with Crohn\u2019s disease. Mod Practical Med. 2022;34(12):1591\u20134.","journal-title":"Mod Practical Med"},{"key":"4975_CR34","unstructured":"Tian XY. Efficacy analysis of vedolizumab in the treatment of moderate to severe ulcerative colitis and Crohn\u2019s disease [master\u2019s thesis]. 2022."},{"key":"4975_CR35","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1093\/ecco-jcc\/jjab076.549","volume":"15","author":"SC Wei","year":"2021","unstructured":"Wei SC, Lin WC, Chang CH, Tu CH, Feng IC, Shieh MJ, et al. Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study). J Crohns Colitis. 2021;15:S428\u201330. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab076.549.","journal-title":"J Crohns Colitis"},{"key":"4975_CR36","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.eclinm.2023.102337","volume":"66","author":"H Yang","year":"2023","unstructured":"Yang H, Huang Z, Li M, Zhang H, Fu L, Wang X, et al. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-na\u00efve or anti-TNF-exposed Crohn\u2019s disease: a multicenter cohort study. EClinicalMedicine. 2023;66:102337. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102337.","journal-title":"EClinicalMedicine"},{"issue":"08","key":"4975_CR37","first-page":"1841","volume":"42","author":"JY Yao","year":"2022","unstructured":"Yao JY, Peng X, Liu T, Zhao JZ, Zhang M, Hu PJ, et al. Short-term efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease: A single-center real-world study. J Clin Pathological Res. 2022;42(08):1841\u20136.","journal-title":"J Clin Pathological Res"},{"issue":"19","key":"4975_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3760\/cma.j.cn112137-20221009-02110","volume":"103","author":"ML Ye","year":"2023","unstructured":"Ye ML, Hu T, Xu LJ, Zhang LP, Yin J, Yu Q, et al. The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents. Natl Med J China. 2023;103(19):1483\u20139. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20221009-02110.","journal-title":"Natl Med J China"},{"issue":"09","key":"4975_CR39","first-page":"977","volume":"32","author":"SM Zhou","year":"2023","unstructured":"Zhou SM, Tian Y, Guo XJ, Huang Q, Song ZJ, Jiang X, et al. Efficacy and safety of Vedolizumab in the treatment of inflammatory bowel disease:a single-center real-world study. Chin J Gastroenterol Hepatol. 2023;32(09):977\u201381.","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"4975_CR40","doi-asserted-by":"publisher","unstructured":"Haga K, Shibuya T, Osada T, Sato S, Fukuo Y, Kobayashi O, et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines. 2022;10(10). https:\/\/doi.org\/10.3390\/biomedicines10102526.","DOI":"10.3390\/biomedicines10102526"},{"issue":"01","key":"4975_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.13705\/j.issn.1671-6825.2022.05.015","volume":"58","author":"MX Huai","year":"2023","unstructured":"Huai MX, Duan XY, Ge WS. Efficacy of vedolizumab in patients with moderate to severe ulcerative colitis. J Zhengzhou University(Medical Sciences). 2023;58(01):117\u201320. https:\/\/doi.org\/10.13705\/j.issn.1671-6825.2022.05.015.","journal-title":"J Zhengzhou University(Medical Sciences)"},{"key":"4975_CR42","doi-asserted-by":"publisher","first-page":"1188751","DOI":"10.3389\/fphar.2023.1188751","volume":"14","author":"K Huang","year":"2023","unstructured":"Huang K, Liu J, Xia W, Tian C, Yao L, Cao Q, et al. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China. Front Pharmacol. 2023;14:1188751. https:\/\/doi.org\/10.3389\/fphar.2023.1188751.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4975_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jcph.1307","volume":"59","author":"K Kobayashi","year":"2019","unstructured":"Kobayashi K, Suzuki Y, Watanabe K, Oda K, Mukae M, Yamada A, et al. A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis. J Clin Pharmacol. 2019;59(2):271\u20139. https:\/\/doi.org\/10.1002\/jcph.1307.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"4975_CR44","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jfma.2021.11.012","volume":"121","author":"CJ Kuo","year":"2022","unstructured":"Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, et al. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc. 2022;121(9):1689\u201395. https:\/\/doi.org\/10.1016\/j.jfma.2021.11.012.","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"4975_CR45","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1007\/s12325-023-02500-6","volume":"40","author":"K Matsuoka","year":"2023","unstructured":"Matsuoka K, Hisamatsu T, Mikami Y, Yamamoto T, Motoya S, Shinzaki S, et al. Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study. Adv Ther. 2023;40(6):2902\u201314. https:\/\/doi.org\/10.1007\/s12325-023-02500-6.","journal-title":"Adv Ther"},{"issue":"1","key":"4975_CR46","doi-asserted-by":"publisher","first-page":"20262","DOI":"10.1038\/s41598-023-47618-3","volume":"13","author":"H Miyazaki","year":"2023","unstructured":"Miyazaki H, Hoshi N, Ishida T, Nishioka C, Ouchi S, Shirasaka D, et al. Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis. Sci Rep. 2023;13(1):20262. https:\/\/doi.org\/10.1038\/s41598-023-47618-3.","journal-title":"Sci Rep"},{"key":"4975_CR47","unstructured":"Qiao HW. Efficacy of verdelezumab combin with glucocorticoid in the treatment of moderate and severe ulcerative colitis [master\u2019s thesis]. 2023."},{"issue":"9","key":"4975_CR48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/jgh3.12630","volume":"5","author":"D Saito","year":"2021","unstructured":"Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, et al. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open. 2021;5(9):1056\u201362. https:\/\/doi.org\/10.1002\/jgh3.12630.","journal-title":"JGH Open"},{"key":"4975_CR49","unstructured":"Sun CX. Vedolizumab and infliximab in the treatment of ulcerative colitis: clinical efficacy analysis [master\u2019s thesis]. 2023."},{"issue":"2","key":"4975_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3760\/cma.j.cn311367-20221128-00589","volume":"43","author":"J Tang","year":"2023","unstructured":"Tang J, Huang ZP, Deng J, Huang ZC, Diao N, Yang HS, et al. The efficacy and safety of vedolizumab in the treatment of 81 cases of active ulcerative colitis: a single center retrospective study. Chin J Digestion. 2023;43(2):117\u201321. https:\/\/doi.org\/10.3760\/cma.j.cn311367-20221128-00589.","journal-title":"Chin J Digestion"},{"issue":"23","key":"4975_CR51","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3760\/cma.j.cn112137-20221216-02663","volume":"103","author":"HY Xiao","year":"2023","unstructured":"Xiao HY, Rao SY, Zhang DL, Ma GL, Xu Y, Jiang Y. Explore the influence of vitamin D supplementation on clinical efficacy and drug retention rate of vedolizumab in patients with ulcerative colitis. Natl Med J China. 2023;103(23):1759\u201366. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20221216-02663.","journal-title":"Natl Med J China"},{"issue":"44","key":"4975_CR52","doi-asserted-by":"publisher","first-page":"e35799","DOI":"10.1097\/md.0000000000035799","volume":"102","author":"J Yan","year":"2023","unstructured":"Yan J, Liu A, Fang L, Wu J, Ding X, Xu Y. The ulcerative colitis endoscopic index of severity score is superior to reflecting long-term prognosis in ulcerative colitis patients treated with vedolizumab. Med (Baltim). 2023;102(44):e35799. https:\/\/doi.org\/10.1097\/md.0000000000035799.","journal-title":"Med (Baltim)"},{"key":"4975_CR53","doi-asserted-by":"publisher","first-page":"I615","DOI":"10.1093\/ecco-jcc\/jjab232.843","volume":"16","author":"A Yoon","year":"2022","unstructured":"Yoon A, Kim K, Oh K, Kim ES, Kim EH, Kim S, et al. Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumab. J Crohns Colitis. 2022;16:I615\u20136.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"4975_CR54","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","volume":"17","author":"FS Macaluso","year":"2023","unstructured":"Macaluso FS, Ventimiglia M, Orlando A. Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. J Crohn\u2019s Colitis. 2023;17(8):1217\u201327. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad043.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"4975_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association. 2017;15(2):229\u2013e395. https:\/\/doi.org\/10.1016\/j.cgh.2016.08.044.","journal-title":"Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association"},{"key":"4975_CR56","doi-asserted-by":"publisher","first-page":"994619","DOI":"10.3389\/fpubh.2022.994619","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu J, Han X, Jiang H, Zhang L, Hu J, et al. Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019. Front Public Health. 2022;10:994619. https:\/\/doi.org\/10.3389\/fpubh.2022.994619.","journal-title":"Front Public Health"},{"issue":"1","key":"4975_CR57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5217\/ir.2019.09160","volume":"19","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, et al. Efficacy and safety of vedolizumab in Crohn\u2019s disease in patients from Asian countries in the GEMINI 2 study. Intest Res. 2021;19(1):83\u201394. https:\/\/doi.org\/10.5217\/ir.2019.09160.","journal-title":"Intest Res"},{"issue":"2","key":"4975_CR58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3760\/cma.j.cn101480-20200430-00047","volume":"05","author":"FY Gao","year":"2021","unstructured":"Gao FY, Wang XY. Advancement of vedolizumab in the treatment of inflammatory bowel disease. Chin J Inflamm Bowel Dis. 2021;05(2):140\u20134. https:\/\/doi.org\/10.3760\/cma.j.cn101480-20200430-00047.","journal-title":"Chin J Inflamm Bowel Dis"},{"issue":"8","key":"4975_CR59","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","volume":"117","author":"S Onali","year":"2022","unstructured":"Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, et al. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn\u2019s Disease Patients\u2019 Failure to TNF-Alpha Inhibitors. Am J Gastroenterol. 2022;117(8):1279\u201387. https:\/\/doi.org\/10.14309\/ajg.0000000000001773.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4975_CR60","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","volume":"157","author":"S Danese","year":"2019","unstructured":"Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, et al. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn\u2019s Disease. Gastroenterology. 2019;157(4):1007\u2013e187. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.038.","journal-title":"Gastroenterology"},{"issue":"1","key":"4975_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S2468-1253(25)00233-X","volume":"11","author":"GR D\u2019Haens","year":"2026","unstructured":"D\u2019Haens GR, L\u00f6wenberg M, Baert F, Bossuyt P, Moln\u00e1r T, Hoentjen F, et al. Vedolizumab in early and late Crohn\u2019s disease (LOVE-CD): a phase 4 open-label cohort study. Lancet Gastroenterol Hepatol. 2026;11(1):12\u201321. https:\/\/doi.org\/10.1016\/S2468-1253(25)00233-X.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04975-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:02:57Z","timestamp":1787662977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4975"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04975-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This manuscript is a Systematic Review and Meta-Analysis, which analyzes data extracted from publicly available literature. It does not involve any new human participants, human data, human tissue, or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"X.Z. and L.G. are employees of Takeda (China) Holdings Co., Ltd, Y.G. and D.Z. have no conflicts of interest to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"525"}}